Literature DB >> 21972212

Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.

Massimo Breccia, Vincenzo Federico, Giuseppina Loglisci, Adriano Salaroli, Alessandra Serrao, Giuliana Alimena.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21972212      PMCID： PMC3186296          DOI： 10.3324/haematol.2011.048991

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  4 in total

1.  Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

2.  Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.

Authors:  Massimo Breccia; Vincenzo Federico; Roberto Latagliata; Caterina Mercanti; Gianna Maria D'Elia; Laura Cannella; Giuseppina Loglisci; Adriano Salaroli; Michelina Santopietro; Giuliana Alimena
Journal:  Leuk Res       Date:  2010-07-01       Impact factor: 3.156

3.  Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Authors:  Matteo G Della Porta; Luca Malcovati; Corinna Strupp; Ilaria Ambaglio; Andrea Kuendgen; Esther Zipperer; Erica Travaglino; Rosangela Invernizzi; Cristiana Pascutto; Mario Lazzarino; Ulrich Germing; Mario Cazzola
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

4.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Authors:  Luca Malcovati; Ulrich Germing; Andrea Kuendgen; Matteo G Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Aristoteles Giagounidis; Barbara Hildebrandt; Paolo Bernasconi; Sabine Knipp; Corinna Strupp; Mario Lazzarino; Carlo Aul; Mario Cazzola
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544
  4 in total
  5 in total

1.  The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.

Authors:  Esther Zipperer; Nina Tanha; Corinna Strupp; Andrea Kündgen; Kathrin Nachtkamp; Judith Neukirchen; Barbara Hildebrandt; Rainer Haas; Norbert Gattermann; Ulrich Germing
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

2.  MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine.

Authors:  Massimo Breccia; Adriano Salaroli; Giuseppina Loglisci; Paola Finsinger; Alessandra Serrao; Giuliana Alimena
Journal:  Haematologica       Date:  2012-02       Impact factor: 9.941

3.  Patient stratification in myelodysplastic syndromes: how a puzzle may become a map.

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Authors:  Susanne Saussele; Marie-Paloma Krauss; Rüdiger Hehlmann; Michael Lauseker; Ulrike Proetel; Lida Kalmanti; Benjamin Hanfstein; Alice Fabarius; Doris Kraemer; Wolfgang E Berdel; Martin Bentz; Peter Staib; Maike de Wit; Martin Wernli; Florian Zettl; Holger F Hebart; Markus Hahn; Jochen Heymanns; Ingo Schmidt-Wolf; Norbert Schmitz; Michael J Eckart; Winfried Gassmann; Andrea Bartholomäus; Antonio Pezzutto; Elisabeth Oppliger Leibundgut; Dominik Heim; Stefan W Krause; Andreas Burchert; Wolf-Karsten Hofmann; Joerg Hasford; Andreas Hochhaus; Markus Pfirrmann; Martin C Müller
Journal:  Blood       Date:  2015-04-27       Impact factor: 22.113

Review 5.  There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.

Authors:  Amer M Zeidan; Rami S Komrokji
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.